Pancreatic Neuroendocrine Tumor G2
4 clinical trials · Condition
◉ Watch Pancreatic Neuroendocrine Tumor G2
| Record | Firm | Date |
|---|---|---|
| Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery (NCT02893930) | National Cancer Institute (NCI) | 2017-04-28 |
| Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery (NCT01229943) | National Cancer Institute (NCI) | 2010-10-15 |
| Real-world Study on Adjuvant Octreotide Therapy in pNETs (NCT06080204) | Changhai Hospital | 2008-03-01 |
Track Pancreatic Neuroendocrine Tumor G2 automatically
Every clearance here is in the API, with alerts when new ones post.